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ABSTRACT 	  
OBJECTIVE. The effect of transdermal estrogen on body composition in 
adolescent female athletes with oligo-/amenorrhea has yet to be examined. 
This is important because female amenorrheic atheltes often express a 
reluctance to take replacement estrogen given concerns that this will cause 
weight gain and accumulation of body fat. In this study we performed a 
randomized, placebo-controlled study to examine the effects of transdermal 
estrogen on body composition parameters, specifically fat mass and lean mass, 
in this specific population. We hypothesized that body composition does not 
change in adolescent athletes with oligo-/amenorrhea receiving transdermal 
estrogen when compared to no estrogen.	   
METHODS. In a cross-sectional study, we examined baseline characteristics of 
51 athletes with oligo-/amenorrhea, 24 athletes with eumenorrhea, and 23 non-
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athlete control subjects. Of the 51 athletes with oligo-/amenorrhea, 11 were 
randomized to no estrogen and 8 were randomized to receive transdermal 
estrogen for a period of 6 months. Changes in body composition parameters 
were assessed. Subjects were 14 to 21 years of age.  
RESULTS. Athletes with oligo-/amenorrhea had lower weight, BMI, fat mass, 
lean mass, trunk fat, and % body fat when compared with athletes with 
eumenorrhea and non-athlete controls at baseline. Athletes with oligo-
/amenorrhea randomized to transdermal estrogen (OAM E+) did not differ from 
athletes randomized to placebo (OAM E-) after 6 months for changes in weight, 
BMI, fat mass, or lean mass.  
CONCLUSIONS. Our results support our hypothesis that transdermal estrogen 
does not change body composition parameters in adolescent athletes with 
oligo-/amenorrhea. After assessing our data we believe further studies are 
necessary to determine the effects transdermal estrogen in this subset of 
athletes.  
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INTRODUCTION 
The Female Athlete Triad 
The female athlete triad refers to a syndrome common among female 
athletes due to the interrelation of three clinical problems. The components of the 
triad include low energy availability, menstrual dysfunction, and decreased bone 
mineral density (BMD) (Nazem & Ackerman, 2012). A recent publication from the 
American College of Sports Medicine (ACSM) on the state of knowledge of the 
triad presented each component as the pathological end of a spectrum ranging 
from normal to frankly abnormal. The other end of the spectrum, referred to as 
the healthy end, comprises optimal energy availability, eumenorrhea, and optimal 
bone health (Figure 1). An athlete’s location on the spectrum depends on her diet 
and exercise habits (Nattiv et al., 2007). Low energy availability directly leads to 
the development of menstrual disorders and subsequently to low BMD (Souza & 
Toombs, 2010).  
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A female athlete’s energy availability plays a valuable role in the 
progression of Triad-related conditions. Energy availability, defined as dietary 
energy intake minus exercise energy expenditure, is responsible for maintaining 
body functions (Nattiv et al., 2007). In the case of the Triad, the energy deficit 
results from some form of dietary restriction, with or without a more severe 
clinical mental disorder such as anorexia nervosa (AN) or bulimia nervosa (BN). . 
Smolak, Murnen, and Ruble (2000) reported some form of disordered eating 
behavior in as many as 62% of athletes involved in lean build sports such as 
gymnastics, ballet, and cross-country running. When energy availability is 
suboptimal, the body is forced to compensate and reduce the amount of energy 
available for growth and reproduction (Liu & Lebrun, 2006). Body weight, 
however, is not directly correlated with energy status and we therefore can not 
assume that low body weight signifies an energy deficit state or that normal body 
weight represents energy stability.  
Menstrual dysfunction related to the Triad occurs secondary to energy 
deficiency because of the dependence of the reproductive system on the net 
state of energy balance. When energy balance becomes too low, the 
hypothalamic-pituitary-ovarian axis is suppressed in order to preserve energy for 
vital functions, resulting in functional hypothalamic amenorrhea (FHA) (Gordon, 
2010; Nazem & Ackerman, 2012). Amenorrhea is the most pathological condition 
related to the Triad. Primary amenorrhea is defined as absence of menarche at 
the age of 16, whereas secondary amenorrhea is classified as the absence of 
4	  	  
menstrual cycles for greater than three months after menarche (Nattiv et al., 
2007). Oligomenorrhea reflects menstrual cycles lasting longer than 35 days and 
eumenorrhea refers to menstrual cycles near the median interval of 28 days for 
young women (21-35 days) (Nattiv et al., 2007;Souza & Toombs, 2010). The 
most important consequence of menstrual irregularities in young women is low 
bone mineral density (Christo et al., 2008; Cobb et al., 2003).  
Functional hypothalamic amenorrhea as a result of a negative energy 
balance stems from a change in gonadotropin releasing hormone (GnRH) pulse 
secretion. GnRH pulsatile secretion from the medial basal hypothalamus is 
decreased in frequency and amplitude, leading to suppression of the 
reproductive axis and consequently conservation of energy (Melmed, Polonsky, 
Larsen, & Kronenberg, 2011). The alteration in GnRH secretion causes the 
downhill effect of decreasing luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH) secretion from the pituitary and ultimately results in 
understimulated ovarian follicles responsible for producing estrogen. This 
progression to estrogen deficiency from a lack of GnRH is shown in Figure 2. 
Functional hypothalamic amenorrhea is reversible and contingent upon adequate 
energy balance to restore proper GnRH secretion (Couzinet et al., 1999; 
Deligeoroglou et al., 2010).  
5	  	  
 
Figure 2. Regulation of the Reproductive Axis by the Hypothalamus. GnRH is released into 
portal circulation from the hypothalamus depending on stimulation from regulating hormones. 
GnRH and other circulating hormones and steroids regulate the formation and release of FSH 
and LH from the pituitary. FSH and LH ultimately act on the ovary to induce the formation of 
estradiol (E2) and progesterone (P).Corticotropin-releasing hormone (CRH). Figure taken from 
Melmed et al., 2011.  
 
 
Hypoestrogenism as a result of functional hypothalamic amenorrhea leads 
to an inability to achieve peak bone mass and low BMD, because estradiol is a 
key regulator of bone metabolism, particularly during the teenage and young 
adult years (Meczekalski, Podfigurna-Stopa, & Genazzani, 2010a). Estradiol 
inhibits osteoclast function by increasing osteoprotegerin (Riggs, 2000), and in 
early puberty, it increases levels of the important bone anabolic hormones, 
growth hormone (GH) and Insulin-like growth factor-1 (IGF-1)(Wennink et al., 
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1991). Adolescents generally experience the largest gain in bone density from 
the rise in estrogen levels that occurs during puberty (Ott, 1991). Girls generally 
achieve up to 90% of their peak bone mass (PBM) by 18 years of age, with 40% 
of bone accrual occurring during puberty (Meczekalski, Podfigurna-Stopa, & 
Genazzani, 2010b).  The Z-score, a subject specific specialized score, compares 
the subject’s BMD obtained by DXA against values from age, race, and sex-
matched peers. The score reflects standard deviations above and below the 
mean for age, gender and race. Low BMD in athletes has been defined by the 
ACSM as a Z-score between -1.0 and -2.0, while osteoporosis, a more 
pathological condition is defined as a Z-score of less than -2.0 with other clinical 
risk factors (Nazem & Ackerman, 2012; Nattiv et al., 2007). Table 1 highlights the 
various BMD definitions based on organization and population. Reporting DXA 
results as BMD Z-Scores is important for our subject selection because the 
values are compared to matched peers, whereas T-Scores compare DXA values 
to peak bone mass, typically achieved only in the early to mid-20s (Nazem & 
Ackerman, 2012). With reports citing BMD values 2-6% lower at the spine, hip, 
and total body among amenorrheic athletes compared with controls (Souza & 
Toombs, 2010) it is important to optimize energy balance to restore menses in 
these athletes and hence increase bone accrual, a process predominantly 
mediated by estrogen in adolescence. 
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Table 1. BMD Definitions. BMD definitions are represented by organization and vary based on 
population. The World Health Organization (WHO) bases the criteria on T-Scores, BMD results of 
postmenopausal women compared to young adult premenopausal women, whereas the 
International Society for Clinical Densitometry (ISCD) and ACSM use Z-Scores, DXA results 
compared to age-matched females, for diagnostic criteria. Table taken from Nazem & Ackerman, 
2012. 
 World Health Organization  
International Society 
for Clinical 
Densitometry  
American College of Sports 
Medicine  
Population  Postmenopausal women  Premenopausal women  Premenopausal female athletes  
Terminology  Osteopenia  Osteoporosis  
BMD 
within 
expected 
range for  
age  
BMD 
below 
expected 
range for  
age  
Low BMD  Osteoporosis  
Criteria  
T-Score: –1 
to –2.5 (1 to 
2.5 SD below 
the average 
value for 
young 
healthy 
women)  
T-Score: ≤	  –2.5 (2.5 SD 
or more below 
the average 
value for 
young healthy 
women)  
Z-Score: > 
–2  
(< 2 SD 
below the 
average 
value for 
age-, sex-, 
and race- 
matched 
controls)  
Z-Score: ≤	  
–2 (2 SD or 
more 
below the 
average 
value for 
age-, sex-, 
and race- 
matched 
controls)  
Z-Score: –1 to 
–2 with 
secondary 
clinical risk 
factors for 
fracture  
(eg, chronic 
malnutrition, 
eating 
disorders, 
hypogonadism, 
glucocorticoid 
exposure, 
previous 
fractures)  
Z-Score: ≤	  –2 with 
secondary 
clinical risk 
factors for 
fracture  
 
8	  	  
Hormone Replacement Therapy 
Bone Mineral Density 
With the primary goal of treatment being to restore regular menstrual 
cycling and enhancement of BMD, 92% of physicians support estrogen 
replacement therapy, routinely prescribing oral contraceptive pills (OCPs) 
(Cumming DC, 1996; Haberland, Seddick, Marcus, & Bachrach, 1995). However, 
the effects of hormone replacement therapy on BMD remain unclear.  Vescovi, 
Jamal, and De Souza (2008) conducted a systematic literature review of 36 
journal articles between 1960 to January 2007 of women with hypothalamic 
amenorrhea receiving hormonal therapeutic strategies. Of the reports pertaining 
to effectiveness of oral contraceptives in restoring BMD, eight studies reported a 
positive effect and nine reported no significant effect after 8-12 months of 
treatment. The inability to significantly enhance BMD in adults with hypothalamic 
amenorrhea by oral estrogen has been accredited to the reduction in IGF-1 
following oral estrogen administration (Ho & Weissberger, 1992). Further 
suppression of already low levels of IGF-1 in hypothalamic amenorrhea by oral 
estrogen (Couzinet et al., 1999) has led to investigation of other forms of 
estrogen replacement therapy.  
The metabolic effects of estrogen are dependent on its route of 
administration (O’Sullivan, Crampton, Freund, & Ho, 1998). Oral estrogen 
suppresses IGF-1 by a hepatic first-pass mechanism, which is avoided with 
transdermal estrogen (Burkman, 2007). Because transdermal estrogen does not 
9	  	  
suppress IGF-1, it may exert a greater impact on BMD than oral estrogen. In a 
study of 417 postmenopausal women in an estrogen deficient state, BMD 
increased with ultra low-dose transdermal estradiol (Ettinger et al., 2004). 
Although these results cannot be extrapolated to adolescent amenorrheic 
athletes, the same rationale applies. The anti-suppressive IGF-1 effects of 
transdermal estrogen are under investigation as a treatment to restore BMD in 
young women with exercise-related amenorrhea.  
Body Composition 
A key concern for athletes is a potential change in body weight and body 
composition with estrogen replacement, and the potential impact of estrogen 
replacement and body composition changes on athletic performance. Functional 
hypothalamic amenorrhea is not only associated with hypoestrogenism, but with 
changes in GH and IGF-1, strong determinants of body composition and resting 
energy expenditure (Dos Reis, De Melo, Meirelles, Vezozzo, & Halpern, 2003). 
Rickenlund and colleagues examined oligo-/amenorrheic athletes between the 
ages of 16-35 after 10 months of oral contraceptive treatment. Results showed 
an increase in weight and fat mass in the oligo-/amenorrhic (OAM) athletes 
compared to eumenorrheic athletes and controls with oral estrogen 
administration (Rickenlund et al., 2004). In a study of postmenopausal women, 
oral estrogen administration was associated with an increase in fat mass and 
decrease in lean mass. The findings were attributed to the decrease in IGF-1 
10	  	  
observed with oral estrogen given the known anabolic effects of IGF-1 on lean 
mass (O’Sullivan et al., 1998).  
To date, no studies have examined changes in body composition in oligo-
/amenorrheic athletes following administration of transdermal estrogen. A study 
in postmenopausal women reported that oral estrogen increased fat mass and 
decreased lean mass, whereas transdermal estrogen caused an increase in lean 
mass, with no changes in fat mass (O’Sullivan et al., 1998). Importantly, the 
ability of transdermal estrogen to prevent chronic IGF-1 suppression may have 
beneficial effects on BMD of adolescent oligo-amenorrheic athletes (OAM) while 
also avoiding the subsequent changes in body composition.  
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Specific Aims 
The effect of transdermal estrogen on body composition in adolescents 
with olig-/amenorrhea has not yet been examined. In this study we performed a 
randomized, placebo-controlled study to examine the impact of physiologic 
estrogen replacement on body composition in adolescent athletes with olig-
/amenorrhea. We hypothesized that body composition, specifically fat mass and 
lean mass, does not change in adolescent athletes with oligo/amenorrhea 
receiving transdermal estrogen when compared to controls not receiving  
estrogen.  Our goal was to determine if transdermal estrogen is a viable 
treatment option for female adolescent athletes concerned about the possible 
effects on their body composition, with the common perception that oral estrogen 
increases weight and fat mass.  
Assessing body composition changes is especially important in this subset 
of adolescent females because the perceived changes due to estrogen 
replacement may lead to an athlete’s refusal of estrogen supplementation rather 
than choosing the treatment needed for optimal bone and overall health. The 
high prevalence of reproductive dysfunction in adolescents, with a corresponding 
deficit in peak bone mass, makes it essential to identify the effects of all possible 
therapeutic interventions.   
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METHODS 
In a cross-sectional analysis at baseline, characteristics of oligo-
/amenorrheic athletes, eumenorrheic athletes, and non-athletic healthy controls 
will be assessed and compared to one another. A 6 month longitudinal analysis 
will determine the effects of transdermal estrogen use on body composition in a 
group of oligo-/amenorrheic athletes.  
Subject Selection 
A total of 51 adolescent athletes who met the criteria for diagnosis of 
oligo-/amenorrhea, 24 athletes with eumenorrhea, and 23 healthy control 
subjects were enrolled in the study. The study was performed at the Clinical 
Research Center of Massachusetts General Hospital (MGH), Boston, MA, USA. 
All subjects were 14 to 21 years of age, and all athletes were endurance 
athletes. Endurance training was defined as at least 4 hours of aerobic weight-
bearing training of the legs or specific endurance training weekly, or at least 20 
miles of running weekly for a period of at least 6 months in the previous year. 
Cyclists and swimmers were excluded because their training does not include 
true weight-wearing activities. Rowers and gymnasts were also excluded given 
that these activities have been associated with a preservation of bone density 
even when associated with amenorrhea, likely consequent to differences in the 
nature of weight bearing and impact.  
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Athletes with amenorrhea were required to have had an absence of 
menses for at least three months, or absence of menarche at ≥ 16 years, 
whereas athletes with oligoamenorrhea were required to have a cycle length 
greater than six weeks for at least six months. Eumenorrheic athletes (EA) were 
defined as those who had at least nine menses (cycle length 21-35 days) in the 
preceding year. Healthy non-athletes were required to not participate in 
organized team sports or engage in weight bearing exercise activity for more 
than two hours a week.  
Subjects were excluded from the study if there was a condition other 
than endurance training that may have caused amenorrhea; including 
hypothyroidism, hyperprolactinemia, premature ovarian failure and PCOS 
(Polycystic Ovarian Syndrome). The use of medications affecting bone 
metabolism, such as estrogen, progesterone, anabolic steroids, glucocortocoids 
(except local application of glucocorticoid creams), phenytoin, and 
phenobarbitone also excluded subjects from enrollment. For the oligo-
/amenorrhic athletes to be randomized to one of the treatment groups, other 
exclusion criteria included a past medical history of conditions that may 
increase the risk of thromboembolism, a current history of smoking, migraines 
or peanut allergies, and any undiagnosed or abnormal genital bleeding.  
Subjects were recruited through mailings to pediatricians, nutritionists, 
therapists, sports medicine specialists, high schools and collages in the New 
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England area, and through advertisements in local newspapers and magazines. 
Prior to performing any testing, we obtained assent from the subject or consent 
from the parents following a briefing of study procedures in the presence of a 
study investigator.  
All subjects were counseled regarding the risk of pregnancy, options for 
birth control measures, and possible side effects from estrogen treatment at the 
time of consent and also at follow-up visits. Minor side effects of estrogen 
include nausea, dizziness, breast tenderness and fullness, headache and 
bloating. More serious side effects include liver and gall bladder disorders, 
thromboembolism, and abnormal vaginal bleeding (protocol 136-138). Subjects 
were advised that transdermal estrogen patches do not provide contraceptive 
protection or protection against sexually transmitted diseases.  
Athletes with OAM were randomized to receive transdermal or no 
estrogen for 12 months. Girls receiving OAM transdermal estrogen also 
received cyclical progesterone for 12 days of every month. All subjects took 
1200 mg of elemental calcium and 800 IU of vitamin D daily.   
Study Treatment  
Of the 51 athletes with oligo-/amenorrhea, data are available for 11 who 
were randomized to no estrogen and 8 who were randomized to receive 
transdermal estrogen for a period of 6 months. All subjects received 1200 mg 
elemental calcium and 800 IU vitamin D daily. The athletes randomized to the 
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transdermal estrogen patch (releasing 100 mcg/day of 17B-estradiol) applied 
the patches biweekly (Sundays/Wednesdays) and received cyclical 
progesterone (micronized progesterone 200 mg) for the first 12 days of the 
month. The doses of estrogen were based on recommended replacement 
doses for this age group.  
Experimental Protocol  
At the screening visit a history, physical examination, and screening labs 
were obtained, including a complete blood count and levels of potassium, ALT 
(alanine aminotransferase), AST (aspartateaminotransferase) TSH, and FSH. 
Bone density and body composition, specifically fat and lean mass, were 
assessed by dual energy X-ray absorptiometry (DXA) at the spine, hip, and total 
body. Spine BMD Z-scores were used to stratify the OAM subjects during 
randomization. A Bouchard 3-day activity record confirmed inclusion criteria for 
endurance training.  
Subjects then completed a baseline visit within eight weeks of the 
screening including a history and physical examination with anthropometric 
measurements and a DXA scan to assess body composition. The same testing 
was performed at a 6 month follow up visit.  
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Body-Composition Measurements  
 Body composition was assessed using DXA (HologicInc., QDR-4500, 
Waltham, MA). Measurements were taken at the lumbar spine, hip, and whole 
body for bone density, and of the whole body for body composition. Body 
composition measures included fat mass, lean mass, percent body fat and trunk 
fat. DXA measures were repeated at the 6-month follow-up visit.  
Statistical Analysis 
We used JMP (version 10, SAS Institute, Inc., Cary, NC) for all analyses 
and set a p value of less than 0.05 on a two-tailed test to indicate significance. 
Three-group comparisons of baseline characteristics of OAM, EA and HC were 
performed by an overall ANOVA, followed by a Tukey-Kramer analysis to 
assess between-group differences while controlling for multiple comparisons 
with normally distributed parametric data. A Kruskal-Wallis test followed by the 
Steel Dwaas All Pairs analysis was using for nonparametric data sets. Weight, 
body mass index (BMI), and lean mass measures required log transformations 
to fit a normal distribution.  
For our primary longitudinal analysis we compared changes in weight, 
BMI, fat mass, and lean mass in oligo-/amenorrheic athletes receiving 
transdermal estrogen (OAM E+) versus oligo-/amenorrheic atheletes not 
receiving estrogen (OAM E-) using a Student t-test. We controlled for 
chronological age, height, and changes in weight in our analysis using 
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multivariate methods for further analysis. We confirmed that changes in weight 
were predictive of subsequent changes in the fat mass, but not lean mass using 
simple linear (Pearson’s) correlation. For our secondary analysis, a paired t test 
was used to compare within group changes in body composition measures over 
6 month.  
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RESULTS 
Baseline Characteristics  
 Bone age, height, and trunk fat did not differ between groups. Athletes 
with oligo-/amenorrhea had significantly lower weight (p=0.03), BMI (p=0.003), 
fat mass (p=0.04), and lean mass (p=0.047) compared with eumenorrheic 
athletes, and lower fat mass (p=0.01) and percent body fat (p<0.0001) when 
compared with the non-athlete control subjects (Table 1, Figure 3). Athletes 
with eumenorrhea had significantly higher lean mass (p=0.004) (Figure 3F) and 
significantly lower percent body fat (p=0.049) (Figure 3G) when compared with 
non-athletes.   
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Table 2. Baseline Characteristics of Oligo-/amenorrheic Athletes (AA), Eumenorrheic 
Athletes (EA), and non-athlete controls (HC). Data are shown as mean + standard deviation 
Abbreviations: n = number of subjects, BMI = body mass index. Significance at p ≤ 0.05 ANOVA 
between groups.  
 Oligo-
/Amenorrheic 
athletes n=51 
Eumenorrheic 
Athletesn=24 
Non-
Athletes 
n=23 
p  
ANOVA  
p 
OAM 
vs 
EA 
p OAM 
vs HC 
p EA 
vs 
HC 
Chronological 
age (years) 
19.3 ± 2.1 19.9 ± 2.1 19.1 ± 
1.7 
0.03a 0.03   
Bone age 
(years) 
17.47 ± 0.99 17.17 ± 1.25 17.54 ± 
1.14 
0.2   
 
Weight (kg) 55.68 ± 7.26 61.80 ± 11.15 56.83 ± 
7.59 
0.02a 0.015   
Height (cm) 165.01 ± 6.54 165.72 ± 8.42 162.60 ± 
7.38 
0.3    
BMI (kg/cm2) 20.42 ± 2.33 22.35 ± 2.31 21.50 ± 
2.52 
0.003a 0.003   
Total fat 
mass (g) 
12332.2 ± 
3862.94 
15141.1 ± 
4392.22 
15962.8 
± 
4916.66 
0.005a,b 0.04 0.01  
Total lean 
mass (g) 
42564.1 ± 
5700.32 
46304.4 ± 
7688.43 
40456.0 
± 
4438.85 
0.006a,c 0.05  0.004 
Trunk fat (g) 4636.63 ± 
1849.44 
5614.45 ± 
2156.6 
5701.83 
± 
2051.87 
0.04    
% body fat  21.46 ± 0.70 23.5 ± 1.02 26.98 ± 
5.23 
0.0001a,c  <0.0001 0.05 
 
aOligo-/Amenorrheic athletes vs. Eumenorrheic athletes p<0.05 
bOligo-/Amenorrheic athletes vs. non-athletes p<0.05 
cEumenorrheic athletes vs. non-athletes p<0.05  
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Figure 3.Baseline Characteristics with 3-group Comparison Results. Oligo-/amenorrheic 
athletes (AA), eumenorrheic athletes (EA), and non-athlete controls (HC).  A: age, B: bone age, 
C: height, D: weight, E: fat mass, F: lean mass. Significance at p ≤ 0.05 ANOVA between 
groups.   
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Figure 3 continued. Baseline characteristics with 3-group comparison results. Oligo-
/amenorrheic athletes (AA), eumenorrheic athletes (EA), and non-athlete controls (HC). G: % 
body fat, H: trunk fat, I: BMI. Significance at p ≤ 0.05 ANOVA between groups.   
 
Changes in Body Composition Parameters 
 In our primary analysis, OAM E+ girls did not differ from OAM E- girls 
over 6 months for changes in weight (p=0.09), BMI (p=0.15), fat mass (p=0.81), 
and lean mass (p=0.30) (Table 3 and Figure 4). OAM E+ females experienced 
a 4.79% and 4.59% increase for weight and BMI, whereas the OAM E- females 
experienced a 0.49% and 0.08% decrease in weight and BMI. Both OAM E+ 
and OAM E- females demonstrated increases in percent change in fat mass 
(6.43%, 8.61%) and decreases in their percent changes in lean mass (-0.16%,  
*	  
*	   *	  
G	   H	  
I	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-1.94%), although the OAM E+ group had a smaller percent increase in fat 
mass and smaller percent decrease in lean mass than the OAM E- group, and 
the increase in weight in OAM E+ was mostly from an increase in lean mass.  
 
Table 3. Changes in Body Composition Parameters in OAM E+ versus OAM E-.  
Δ=difference in, 6 months compared with baseline. Significance at p ≤ 0.05 ANOVA between 
groups.  
 AN E+ AN E- p values 
Δ Weight (kg) 2.79 ± 5.59 -0.39 ± 2.04 0.09 
Δ BMI (kg/cm2) 0.89 ± 1.84 -0.05 ± 0.8 0.15 
Δ Fat mass (g) 730.6 ± 3066.1 1062.9 ± 2819.5 0.81 
Δ Lean mass (g) -92.6 ± 1262.6 -916.28 ± 1910.52 0.3 
 
 
	  
Figure 4. Percent Changes in Body Composition Parameters in OAM E+ versus OAM E-.  
Percent change in body composition measures in oligo-/amenorrheic females randomized to no 
estrogen (black bars) and females randomized to estrogen (grey bars).  
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We also examined differences in OAM E- girls versus OAM E+ girls after 
controlling for (1) baseline age, height, and weight changes, and for (2) baseline 
age and height. There were no correlations of baseline age, height, and weight 
changes with changes in lean mass. Correlation analysis did show an 
association between changes in weight and absolute and percent changes in 
fat mass (r=0.59 p=0.0075; r=0.55 p=0.014). Differences between OAM E- girls 
vs. OAM E+ girls for changes in fat mass over 6 months became significant in 
the positive direction after controlling for changes in weight over this period 
(Table 4).  Weight changes significantly predicted changes in fat mass in OAM 
E+ girls, but not OAM E- (Figure 5). Multivariate analysis did not reveal any 
other significant confounding variables.  
A 	  B 	  
 
Figure 5: Associations Between Changes in Weight and Changes in Fat Mass. A) OAM E+ 
girls change in fat mass correlated positively with changes in weight (r=0.81, p=0.014), whereas 
B) OAM E- girls did not have a significant correlation between change in fat mass and change in 
weight (r=0.57, p=0.067).  
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Table 4: Multivariate Analysis Results. Changes in body composition parameters in OAM E- 
versus OAM E+ girls after controlling for covariates. Significance at p ≤ 0.05 ANOVA between 
groups.   
Body composition 
changes 
p  OAM E- 
versus OAM E+ 
pa pb 
Δ Fat mass (g) 0.81 0.035* 0.9 
Δ Lean mass (g) 0.3 0.58 0.76 
 
paValue after controlling for baseline age, height, and changes in weight 
pbValue after controlling for baseline age and height 
 
Additionally, on secondary analysis using a paired t-test, we found no 
significant changesover 6 months within OAM E+ girls and within OAM E- girls 
for weight, BMI, fat mass, and lean mass (Table 5 and Figure 6).  
Table 5.Within Group Analysis of OAM E+ and OAM E- Groups Body Composition 
Parameters After 6 Months of Treatment.  A paired t test compared differences from BL to 
6M within a group for weight, BMI, fat mass, and lean mass. Significance at p ≤ 0.05.  
 
 BL 6M Mean 
Difference 
P-Value 
Weight E- 57.3909 57 0.39091 0.5388 
Weight E+ 53.0625 55.85 -2.7875 0.2010 
BMI E - 21.246 21.1923 0.05373 0.8290 
BMI E + 19.5536 20.4454 -0.8918 0.2129 
Fat Mass E - 13193.9 14256.8 -1062.9 0.2397 
Fat Mass E + 10921.1 11651.8 -730.64 0.5219 
Lean Mass E - 43200.5 42284.2 916.282 0.1428 
Lean Mass E 
+ 
43911.5 43818.9 92.6375 0.8415 
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A B  
Figure 6. Mean Differences from Within Group Analysis of Body Composition 
Parameters. (A) weight and BMI and (B) fat and lean mass mean differences. Results are 
reported as mean differences between BL and 6M.  
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DISCUSSION 
This is the first study to examine the effects of transdermal estrogen on 
body composition in adolescents with oligo-/amenorrhea. We demonstrate that 
transdermal estrogen does not significantly change fat or lean mass over the 6 
month period of treatment in oligo-/amenorrheic athletes compared to other 
oligo-/amenorrheic athletes who do not receive  estrogen therapy. Our findings 
are especially relevant to this subset of adolescent athletes because of their 
stage of bone development and the possible deleterious effects of long term 
amenorrhea. Adequate estrogen levels are essential to restore bone accrual 
and achieve an optimal BMD. These data suggest transdermal estrogen may 
serve as a viable treatment option for adolescent oligo-/amenorrheic athletes 
without significantly affecting body composition. 
Baseline Findings 
 Our analysis included a cross-sectional examination of baseline 
characteristics in oligo-/amenorrheic athletes versus eumenorrheic athletes and 
non-athlete controls. It is important to identify individuals with Triad-related 
dysfunction and determine specifically what differentiates the different groups. 
One way is to recognize the major contributors to the components of the triad. 
Cristo and colleagues (2008) found that lean mass and BMI were the strongest 
predictors of bone density in athletes. Our results also indicate differences in 
body composition between the three subject groups that would predispose them 
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to variable BMD measures. Importantly, oligo-/amenorrheic athletes had 
significantly lower BMI and lean mass than eumenorrheic athletes (Table 2 and 
Figure 3).  
 Baseline body composition measures are also important to understand 
and differentiate because of their relation to energy availability. Low energy 
availability begins the progression towards menstrual dysfunction and low 
estrogen levels, ultimately leading to low BMD. Fat mass reflects energy stores, 
and thus the chronic state of energy availability in any individual. Low fat mass 
indicates low energy availability, and is a predictor of menstrual dysfunction 
(Misra et al., 2006). Consistent with this, the OAM athletes had significantly 
lower fat mass than EA and non-athletes..  
 Fat mass is also an important baseline characteristic to compare 
between groups because fat related hormones possess the ability to alter 
reproductive function. Low fat mass not only indicates a disruption in energy 
balance, but could explain the mechanism leading to amenorrhea, namely from 
changes in hormones that are secreted by fat (such as leptin) or are regulated 
by fat (such as ghrelin and peptide YY) and then impact GnRH pulsatility. 
Leptin, a hormone secreted by fat mass, has previously been explored as an 
influence on the hypothalamic-pituitary-ovarian axis. Lower leptin levels as a 
result of low fat mass have been linked to altered LH pulsatility. A recent study 
on adolescent athletes demonstrated significantly lower fat mass and leptin 
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levels in amenorrheic subjects compared to eumenorrheic subjects and nonb-
athletic controls (Ackerman et al., 2012). Figure 6 highlights the progression 
from a decrease in fat mass leading to lower leptin levels and eventually 
amenorrhea. The orexigenic hormone ghrelin, secreted by gastric oxyntic cells, 
is inversely related to fat mass and also linked to the hypothalamic-pituitary-
ovarian axis. In the same study by Ackerman and collegues (2012), adolescent 
athletes demonstrated an independent association between higher ghrelin 
levels and lower fat mass, and an inverse association with altered LH pulsatility. 
The associations between fat related hormones and changes to LH pulsatility 
reflect an endocrine link between a low energy state, low fat mass and altered 
GnRH or LH pulsatility in adolescent athletes.  
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Figure 7. The Hormonal Mechanism of Leptin Secretion and Female Reproductive 
Consequences. While in a state of negative energy balance and low fat mass leptin in secreted 
from fat cells. The reproductive system is subsequently shut down because of reduced GnRH 
production, therefore reducing LH and FSH. This progression leads to hypothalamic 
amenorrhea. Image taken from Sharpe and Franks, 2002.  
 
These data indicate that adolescent oligo-/amenorrheic athletes can be 
differentiated from adolescent eumenorrheic athletes by weight, BMI, fat mass, 
and lean mass.  
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Comparison of Oral and Transdermal Estrogen Treatment  
Oral estrogen is being used as a treatment option for adolescents with 
oligo-/amenorrhea, however, studies have reported changes in body 
composition following treatment with estrogen. In a subset of oligo/amenorrheic 
endurance athletes between the ages of 16-35, who received oral estrogen for 
10 months, there was a significant increase in weight and fat mass with 
estrogen administration (Rickenlund et al., 2004). Body composition changes 
due to estrogen have previously been attributed to the relationship between 
estrogen and GH. Oral estrogen exerts effects in the liver by inhibiting the 
metabolic effects of GH by decreasing IGF-1 production and fat oxidation. The 
clinical consequences in postmenopausal women include a decrease in lean 
mass and increase in whole body fat mass (Leung, Johannsson, Leong, & Ho, 
2004). The IGF-1 mediated effects of GH are impacted by oral estrogen and 
may cause changes in body composition from oral estrogen administration.  
Transdermal estrogen, which does not suppress IGF-1, should be 
explored as a treatment option in this subset of individuals to restore bone 
health without the possible ‘negative’ effects on body composition. Based on 
this rationale, we hypothesized that administration of transdermal estrogen to 
oligo-/amenorrheic athletes between the ages of 14-21, compared to no 
estrogen therapy, should not significantly alter body composition parameters. 
Our results support our hypothesis, and we show that transdermal estrogen 
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does not change weight, BMI, fat mass, or lean mass between groups. 
Additional multivariate analysis revealed that changes in fat mass across 
groups were associated with changes in weight, and adjusting for weight 
changes led to a significant difference between groups for an increase in fat 
mass.  
 It is possible that our study was underpowered and did not completely 
reveal the interaction between transdermal estrogen usage and body 
composition changes in oligo-/amenorrheic girls. We found no significant 
differences between OAM E+ versus OAM E- for weight, BMI, fat mass, and 
lean mass changes. However, the data did suggest a trend towards differences 
between the treatment groups (Table 3). Adequate sample size may reflect 
changes in body composition measures, and further assist our understanding of 
how different forms of estrogen specifically impact fat mass and lean mass in 
athletes.  
 We found no significances for our within group analysis for changes in 
weight, BMI, fat mass, and lean mass in OAM E+ girls (Table 5), indicating that 
transdermal estrogen therapy does not cause weight or body composition 
changes. This may help promote transdermal estrogen as a form of hormone 
replacement therapy for adolescent oligo-/amenorrheic athletes concerned 
about an increase in weight or an impact on performance. Additionally, if 
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anything, our study showed a non-significant decrease in fat mass in the OAM 
E+ group, as well as an increase in lean mass.  
Limitations 
 Data from this study does further support transdermal estrogen as a 
possible treatment option for adolescent athletes, but the results should be 
considered as a starting point for further investigation. Although outcomes 
presented were statistically viable, small sample size limited the power of the 
study. There were only eight athletes receiving the transdermal patch and 
eleven athletes with no treatment. Additionally, the 6-month treatment time 
frame limited the longitudinal analysis of body composition changes. Subjects 
should be followed over a longer duration to determine whether the observed 
lack of changes in fat and lean mass with treatment persists over time (Souza & 
Toombs, 2010).  
 The number of treatment groups also limits the findings from the study. 
Although we hypothesized that transdermal estrogen would not change body 
composition parameters compared to no treatment, the addition of an oral 
estrogen treatment group would provide more insight to the mechanisms 
whereby these changes may have occurred.  Previous studies on 
postmenopausal women have compared oral estrogen to transdermal estrogen 
and found significant differences between the two groups for body composition 
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changes (Osullivan). There were not enough subjects receiving oral estrogen 
treatment to compare within our cohort at this time.   
Future Studies 
 The results of our study, as well as its limitations, indicate the need to 
include other parameters in future investigations. Hormone levels, specifically 
IGF-1, should be monitored in order to more accurately describe the 
mechanisms whereby estrogen replacement therapy affects body composition, 
particularly with respect to route specific actions. BMD measures should also be 
included in the analysis when assessing transdermal estrogen as a treatment to 
improve BMD without subsequent changes in body composition. As mentioned 
earlier, more subjects should be assessed over a longer period of time to 
increase the power of the study, and should also be compared to an oral 
estrogen treatment group.  
 Although our findings are consistent with findings from previous studies 
examining the effects of transdermal estrogen on body composition, our data 
support the need to examine these effects among specific groups of subjects. 
The profiles of adolescent oligo-/amenorrheic adolescent athletes and 
postmenopausal women both reflect a state of estrogen deficiency, but confer 
different changes on the body based on weight. Sullivan and colleagues (1998) 
proposed that body composition changes observed in women receiving oral 
estrogen may be attributable to increases in fat mass and decreases in lean 
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mass from aging. Transdermal estrogen has also been proposed as a strategy 
to increase BMD in adolescents with AN, and may cause changes in body 
composition over time that differ from those in athletes given that AN subjects 
having even lower IGF-1 levels at baseline than athletes (Misra et al., 2011).  
Findings related to body composition changes with estrogen treatment cannot 
be assumed to be the same for all conditions and thus further studies are 
necessary to study the effects of transdemal estrogen in different subject 
cohorts.   
Our subset of athletes also requires specific attention to the time of year 
during which measurements are recorded. Any athlete’s body composition has 
the capacity to change depending on whether they are in or out of season. The 
activities of our subjects are mostly seasonal. Therefore, body composition 
parameters are likely to vary through out the year. It is important to demonstrate 
the effects of transdermal estrogen on body composition while controlling for 
these factors.  
After identifying transdermal estrogen as a beneficial treatment option to 
restore BMD without effecting body composition or performance, it is important 
to assess the effects of different estrogen doses on body composition and 
performance. Subjects in this study, OAM female athletes between the ages of 
15 and 21, received 100 mcg/day of 17B-estradiol transdermally, similar to a 
study of postmenopausal women in which the subjects also received 100 
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mcg/day 17B-estradioltransdermally (O’Sullivan et al., 1998). However, in a 
group of 24-34 year old amenorrheic adults, the transdermal patches used 
delivered only 50 mcg estradiol/day (Cumming DC, 1996). Variances in the 
amount and type of estrogen used in various studies demonstrate the need to 
systematically compare and explore the effects of various doses and types of 
transdermal estrogen on body composition.  
Conclusion 
 We have demonstrated that transdermal estrogen does not significantly 
change lean mass or fat mass over a 6-month period compared to no treatment 
in a group of adolescent female athletes. Although our findings support the use 
of transdermal estrogen as a potential treatment option for adolescent athletes 
with amenorrhea, changes in diet and exercise habits should be the primary 
treatment for athletes with triad related symptoms (Souza & Toombs, 2010). 
The origin of bone and menstrual disturbances can be attributed to changes in 
energy balance that can be preserved by improving nutritional status. 
Adolescent athletes should be encouraged to engage in the proper balance of 
physical activity and eating as a way to ensure optimal bone development.   
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